Document Type : Original Article
Authors
1
Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for reproductive biomedicine, ACECR, Tehran, Iran
2
-
3
Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR
4
3- Department of Epidemiology and Reproductive Health, Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
5
-2- Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
10.22074/ijfs.2023.2008905.1513
Abstract
Background: Recently, there is a debate about what dose of gonadotropin-releasing hormone (GnRH) agonist used for oocyte triggering in patients with polycystic ovarian syndrome (PCOS) at risk of ovarian hyperstimulation syndrome (OHSS) can be more effective; therefore, this study was designed to detect whether repeated dose GnRH agonist used for oocyte triggering in these patients can improve the outcomes of controlled ovarian stimulation (COS) in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles.
Methods: 70 PCOS women who were candidates for IVF/ICSI cycle with standard antagonist protocol at Royan institute were enrolled from May 2020 to June 2022. Patients at the risk of OHSS had estradiol more than 3000 pg/ml at the day of trigger were randomly allocated into two groups: in group A (control group), 0.2 mg of Triptorelin (Decapeptyl) was administered for final oocyte maturation and in group B (experimental group), a repeated dose of 0.1 mg of Decapeptyl 12 hr. after the first dose was prescribed. The IVF/ICSI outcomes were compared.
Results: Ultimately 35 women from the study group and 33 patients from the control group had completed the treatment cycle. The two groups were comparable in terms of demographics characteristics, baseline hormonal profiles and PCOS phenotypes. The COS results indicated that the dosage of gonadotropin consumed, stimulation duration, as well as the number of retrieved oocytes, oocyte maturation rate and oocyte recovery ratio had no significant difference between groups. No significant difference was found in terms of the number of blastocyst and cleavage embryos as well as the quality of obtained embryos between the groups. The mild to moderate OHSS rate was significantly lower in the study group (P=0.038).
Conclusion: The second dose of GnRH agonist 12 hr. after the first dose did not improve number and maturity of oocytes as well as pregnancy outcomes in PCOS patients
Keywords
Main Subjects
)